Pharma BD Deal Intelligence

Bristol-Myers Squibb Company / Repertoire Immune Medicines Inc.

2024 · Licensing/Option · $1.9B · Complete

Repertoire Immune Medicines and Bristol Myers Squibb announced multi-year strategic collaboration to develop tolerizing vaccines for up to three autoimmune diseases. Repertoire receives $65M upfront and up to $1.8B in development, regulatory and commercial milestones plus tiered royalties. Leverages Repertoire's DECODE platform mapping the T-cell immune synapse.

Key facts

• Announced Apr 29, 2024
• Closed Apr 29, 2024
• Deal value $1.9B
• Deal type Licensing/Option
• Therapeutic area Autoimmune diseases
• Indications Autoimmune diseases
• Key assets DECODE platform-derived tolerizing vaccines (up to 3 autoimmune targets)
• Mechanism T-cell targeted tolerizing vaccines (DECODE platform)

← Browse all deals  ·  How we score deals